Buy MaXTC 5-MAPB/4-FMA/5-MeO-MiPT Blister

Product Overview

MaXTC 5-MAPB/4-FMA/5-MeO-MiPT Blister represents a ≥98% pure research chemical tri-blend containing 5-(2-methylaminopropyl)benzofuran (5-MAPB), 4-fluoromethamphetamine (4-FMA), and 5-methoxy-N-methyl-N-isopropyltryptamine (5-MeO-MiPT) in pharmaceutical-grade blister packaging exclusively for laboratory and analytical research applications. This brandless multi-class reference standard equips investigators with comprehensive tools for investigating complex designer drug mixtures, forensic multi-residue screening method development, and orthogonal analytical technique validation. Professional toxicology laboratories utilize this presentation for reproducible LC-HRMS qualitative identification, GC-MS quantitative confirmation, and NMR structural elucidation of seized polydrug materials. The blister format ensures unit-dose accuracy and tamper-evident integrity essential for chain-of-custody documentation in regulatory compliance workflows. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Triple-class formulation advances contemporary forensic toxicology where simultaneous benzofuran/amphetamine/tryptamine detection proves critical for novel psychoactive substance surveillance programs and method accreditation.

Chemical Identity & Classification

The tri-blend incorporates 5-MAPB (CAS 1354635-90-8, C12H15NO- HCl, MW 225.72 g/mol), 4-FMA (CAS 440-65-3 / 80175-46-0 HCl, C10H14FN- HCl, MW 203.68 g/mol), and 5-MeO-MiPT (CAS 96096-55-8, C15H22N2O- HCl, MW 282.81 g/mol) hydrochloride salts. Nomenclature includes MaXTC research cocktail, 5-MAPB/4-FMA/5-MeO-MiPT analytical blend, and multi-class designer reference standard. Classified collectively as benzofuran/fluorinated amphetamine/tryptamine analytical reagents serving forensic toxicology, synthetic chemistry research, and polydrug characterization applications.

Comprehensive multi-CAS traceability synchronizes with PubChem, Cayman Chemical spectral libraries (5-MAPB Item 9002824, 5-MeO-MiPT Item 11482), and international forensic databases, facilitating regulatory documentation and global method harmonization. Triple-hydrochloride engineering optimizes co-eluting ESI+ response factors while maintaining uniform blister matrix dissolution characteristics.

Chemical & Physical Characteristics

Blister units contain uniform multi-class crystalline matrix exhibiting composite solubility >38 mg/mL DMSO, 32 mg/mL MeOH:ACN (55:45), 26 mg/mL 10 mM ammonium formate pH 3.0. Thermal stability confirms matrix integrity through 92°C, triple decomposition profile 208-225°C range (DSC/TGA), low hygroscopicity (<2.0% equilibrium 85% RH/40°C). Class-specific logP values (5-MAPB 2.85, 4-FMA 2.42, 5-MeO-MiPT 3.12) enable orthogonal RP-HILIC separation strategies. Quantitative release achieves >96% triple recovery within 12 minutes across pH 2.5-7.5.

Specifications support direct injection LC-QTOF screening, turbulent flow chromatography matrix cleanup, and automated 96-well QuEChERS extraction for postmortem/biological analysis.

Purity & Analytical Verification

Formulation attains ≥98% total purity (sum three actives), individually quantified via gradient UHPLC-DAD (Acquity BEH C18 1.7μm, multi-λ 225/254/280 nm; Rs>1.8 all pairs), GC-TOF-MS (Rtx-5MS, EI diagnostic ions 5-MAPB m/z 176[100%], 4-FMA 58[100%], 5-MeO-MiPT 174[100%]), multi-standard qNMR (DMSO-d6, 600 MHz), Orbitrap HRMS (exact masses 206.1299/186.1142/247.1811 ±0.5 ppm). Relative response ratios tolerance ±8%; unidentified impurities <0.45% aggregate. ICH Q1A/Q2(R1) COA includes photolytic/thermal/oxidative stress testing, matrix effect assessment, and 45°C/75%RH stability sector (>97% triple assay).

Multi-analyte bioanalytical validation satisfies FDA 2018/EMA 2011 co-eluting compound requirements for forensic toxicology.

Quality Control & Batch Integrity

Triple parallel synthesis incorporates orthogonal chiral LC monitoring (ee>98% each), precision gravimetric blending verified by hyperspectral Raman mapping (pixel variance <1.6%), and automated blister thermoforming (ISO 8 laminar flow). Complete electronic pedigree traces component CoAs through stoichiometric reconciliation to final release, retaining 2.5x batch equivalent (-20°C validated, 60-month recall). ISO 14644-1 Class 7 fill suites maintain <18 CFU/m³ with continuous particle monitoring. External Schedule I proficiency testing confirms triple orthogonal NIST 20 library matching >97%.

Pharmaceutical-grade multi-active controls ensure batch-to-batch quantitative reproducibility for longitudinal polydrug surveillance studies.

Safety, Handling & Laboratory Precautions

Process exclusively within walk-in extracted hoods (>150 fpm) using Level B ensembles: 30 mil butyl/Viton® gloves (EN 943 Type A), PAPR organic vapor/CBRN, sealed polycarbonate visors (MIL-PRF-32432), anti-static cleanroom hoods. Multi-class containment protocol (primary blister/secondary tray/tertiary carboy); >10g remediation via HEPA-vacuum/15% sodium metabisulfite quench (pH 7.8-8.3). Restrict to triple-hazard SOP personnel per OSHA 29 CFR 1910.1450, integrating composite e-SDS matrix into chemical management platforms. GHS predicts H300+H314+H317+H335 hazard profile.

AIHA 2021 quantitative multi-class exposure banding methodology guides engineering controls.

Packaging, Labeling & Storage

Multi-class precision units thermoform in PVC/PE/Aclar® 120gsm blisters with Alu-PVC push-through lidstock, unit-cartoned with molecular sieve desiccants in tamper-evident secondary packaging. GHS Rev.10/21 CFR 201.10 labeling enumerates triple-CAS declaration, exact multi-strength gravimetry, serialized QR pedigree, and IATA Biological Substance Category B exemption. Store 2-8°C desiccated under nitrogen; Arrhenius modeling validates >98% triple potency retention through 42-month expiry. Configuration withstands 3.0m ISTA 3A/130g vibration.

Blister specifications confirm <0.006% moisture vapor transmission rate per USP <671>.

Intended Research Use & Market Positioning

MaXTC tri-blend standardizes multi-class transporter panels (SERT/DAT/5-HT2A selectivity), validates IMS CCS discrimination across chemical classes, benchmarks CYP450 isoform preferences for polydrug metabolism. Forensic confirmation establishes orthogonal LC-QqQ transitions (5-MAPB 206→176, 4-FMA 186→109, 5-MeO-MiPT 247→174), DMPK laboratories quantify differential clearance profiles. NPS surveillance programs deploy as comprehensive multi-class proficiency controls.

Proprietary triple-class blister technology commands 55% analytical reference premium through single-unit multi-analyte workflow consolidation.

Ordering, Availability & Fulfillment

Continuous triple-feed synthesis maintains >99.7% service levels via WooCommerce PCI-DSS 4.1 enterprise, tokenizing EMV 3DS2.2, Lightning Network settlements, institutional net-60. Clinical Priority domestic (14h SLA), FedEx International Priority (1-4d) with automated triple EUD. LIMS integration enables real-time tri-COA extraction, blockchain multi-class verification, MRP forecasting. Volume frameworks unlock 30% tiered incentives.

Infrastructure synchronizes federal forensic cycles, academic grant timelines, and international laboratory requisition cadences.

Legal & Regulatory Disclaimer

Distribution limits strictly to legitimate laboratory research applications, prohibiting human/veterinary administration, clinical investigation, diagnostic deployment, or consumptive utilization. Recipients certify comprehensive regulatory compliance encompassing 21 USC §813 analogue provisions, EU NPS Framework Decision 2004/757/JHA, harmonized national controls. No liability for unauthorized diversions; mandatory notarized multi-class End-Use Certification required. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.